Table 4 Subgroup analyses of ORR in bTMB high and bTMB low NSCLC patients
Variable | No. 0f cohorts | No. of patients | bTMB high | bTMB low | ||||
|---|---|---|---|---|---|---|---|---|
bTMB high/bTMB low | Pooled HR (95% CI) | P | I2 (%) | Pooled HR (95% CI) | P | I2 (%) | ||
Line of therapy | ||||||||
 1 | 4 | 441/969 | 2.55 (1.16–5.59) | < 0.01 | 0 | 0.62 (0.41–0.93) | 0.02 | 41 |
  ≥ 2 | 2 | 221/573 | 2.74 (1.75–4.30) | 0.02 | 5.9 | 0.73 (0.45–1.18) | 0.19 | 4.9 |
Therapy regimen | ||||||||
 Anti-PD-L1 vs CT | 3 | 368/967 | 1.98 (1.15–3.41) | 0.02 | 0 | 0.64 (0.47–0.89) | < 0.01 | 0 |
 Anti-PD-L1 plus anti-CTLA-4 vs CT | 1 | 134/389 | 3.44 (1.62–7.31) | < 0.01 | N/A | 0.44 (0.27–0.71) | < 0.01 | N/A |
 Anti-PD-1 plus CT vs CT | 2 | 160/186 | 3.75 (1.79–7.88) | < 0.01 | 0 | 1.01 (0.54–1.86) | 0.99 | 0 |
Type of NGS panel | ||||||||
 Foundation one | 2 | 221/573 | 2.55 (1.16–5.59) | 0.02 | 0 | 0.73 (0.45–1.18) | 0.19 | 4.9 |
 Gardant OMNI | 3 | 379/920 | 2.62 (1.52–4.52) | < 0.01 | 28 | 0.63 (0.38–1.03) | 0.06 | 60.6 |
 OncoScreen Plus | 1 | 62/49 | 4.04 (1.13–14.43) | 0.03 | N/A | 0.63 (0.19–2.13) | 0.46 | N/A |
PD-L1 expression | ||||||||
 Unselected for PD-L1 | 6 | 662/1542 | 2.69 (1.84–3.93) | < 0.01 | 0 | 0.64 (0.47–0.86) | < 0.01 | 25.7 |
Cut-off value (mut/meg) | ||||||||
 16 | 2 | 221/573 | 2.55 (1.16–5.59) | 0.02 | 0 | 0.73 (0.45–1.18) | 0.19 | 4.9 |
 Others | 4 | 441/969 | 2.74 (1.75–4.30) | < 0.01 | 0 | 0.64 (0.47–0.86) | 0.02 | 41 |